PSMA CAR-T

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NamePSMA CAR-T
Drug Alias NameTGFbDNRII-expressing anti-PSMA CAR T-cell therapy (University of Pennsylvania/Kite Pharma)TGFbDNRII-expressing anti-PSMA CAR T-cell therapy (University of Pennsylvania/Tmunity)anti-PSMA CAR T-cell therapy (University of Pennsylvania)CART-PSMA-TGFbRDNanti-PSMA CAR T-cell therapy (University of Pennsylvania/Kite Pharma)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionProstate-Specific Membrane Antigen modulatorsTransforming growth factor beta inhibitors
TargetsProstate-Specific Membrane AntigenTransforming growth factor beta
Therapy Area/IndicationsHormone-Resistant Prostate NeoplasmsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Pennsylvania
China Registration ClassN/A

Develop Information

Active CompaniesKite Pharma IncUniversity Of Pennsylvania
Inactive CompaniesTmunity Therapeutics Inc
Active IndicationsHormone-Resistant Prostate NeoplasmsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A